These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2394 related items for PubMed ID: 7992096

  • 21. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 22. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
    Keilholz U, Eggermont AM.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S99-103. PubMed ID: 10685668
    [Abstract] [Full Text] [Related]

  • 23. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
    Legha SS, Buzaid AC.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 9):27-32. PubMed ID: 8054006
    [No Abstract] [Full Text] [Related]

  • 24. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
    Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC.
    Clin Cancer Res; 2000 Oct 15; 6(10):3895-903. PubMed ID: 11051235
    [Abstract] [Full Text] [Related]

  • 25. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R, Italian Melanoma Intergroup.
    Melanoma Res; 2009 Apr 15; 19(2):100-5. PubMed ID: 19262411
    [Abstract] [Full Text] [Related]

  • 26. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N.
    J Clin Oncol; 1998 May 15; 16(5):1752-9. PubMed ID: 9586888
    [Abstract] [Full Text] [Related]

  • 27. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB.
    Head Neck; 2008 Dec 15; 30(12):1592-8. PubMed ID: 18798304
    [Abstract] [Full Text] [Related]

  • 28. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH, Mansat E, Legoux B, Litoux P, Dreno B.
    Ann Dermatol Venereol; 1996 Dec 15; 123(9):538-42. PubMed ID: 9615103
    [Abstract] [Full Text] [Related]

  • 29. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R.
    J Clin Oncol; 2006 Jul 01; 24(19):3157-63. PubMed ID: 16809738
    [Abstract] [Full Text] [Related]

  • 30. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S.
    Anticancer Drugs; 2008 Feb 01; 19(2):201-7. PubMed ID: 18176117
    [Abstract] [Full Text] [Related]

  • 31. Our experience with interferon alpha: metastatic malignant melanoma.
    Merimsky O, Chaitchik S.
    Mol Biother; 1992 Sep 01; 4(3):135-8. PubMed ID: 1445667
    [Abstract] [Full Text] [Related]

  • 32. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
    Feun L, Marini A, Moffat F, Savaraj N, Hurley J, Mazumder A.
    Cancer Invest; 2005 Sep 01; 23(1):3-8. PubMed ID: 15779861
    [Abstract] [Full Text] [Related]

  • 33. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N.
    Br J Cancer; 2000 Mar 01; 82(6):1158-62. PubMed ID: 10735499
    [Abstract] [Full Text] [Related]

  • 34. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA.
    Melanoma Res; 1998 Apr 01; 8(2):149-55. PubMed ID: 9610868
    [Abstract] [Full Text] [Related]

  • 35. [Treatment of malignant melanoma: recent advances and perspectives].
    Saida T.
    Gan To Kagaku Ryoho; 1997 Jan 01; 24(1):10-5. PubMed ID: 9020939
    [Abstract] [Full Text] [Related]

  • 36. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U, Suciu S, Eggermont AM.
    Br J Cancer; 2000 Jul 01; 83(1):6-7. PubMed ID: 10883660
    [No Abstract] [Full Text] [Related]

  • 37. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W.
    J Clin Oncol; 2001 Jul 01; 19(13):3194-202. PubMed ID: 11432886
    [Abstract] [Full Text] [Related]

  • 38. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
    Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N.
    Ann Oncol; 2006 Apr 01; 17(4):571-7. PubMed ID: 16469753
    [Abstract] [Full Text] [Related]

  • 39. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial.
    Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J.
    Mol Biother; 1992 Mar 01; 4(1):4-9. PubMed ID: 1627272
    [Abstract] [Full Text] [Related]

  • 40. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
    Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK.
    J Clin Oncol; 2014 Nov 20; 32(33):3771-8. PubMed ID: 25332243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 120.